Arkolith/Insider Trading/PCSA/Form 4/A

Young David

Pres. Research & Development, DirectorProcessa Pharmaceuticals, Inc. (PCSA) · full profile →Form 4/A · filed Feb 18, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 29, 2025Grant(A)125K—$0125K
Jan 29, 2025Grant(A)62K—$062K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0000897069-25-000294) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML